Brought to you by 
Genzyme helps PTC develop and commercialize PTC124; terminated
30 May 2013
Executive Summary
Genzyme will help PTC Therapeutics develop and commercialize its oral small-molecule Phase II PTC124 for genetic disorders caused by nonsense mutations. PTC keeps rights to the drug in the US and Canada, while Genzyme gets exclusive commercialization rights in all other countries.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme helps PTC develop and commercialize PTC124; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice